Compare Incyte Corporation (INCY) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Marqeta Inc — how do they compare? Incyte Corporation trades at $118 (market cap $23.11B), while Marqeta Inc trades at $17.25 (market cap $1.85B). The key difference: Incyte Corporation is far larger — about 12.5× Marqeta Inc's market cap, and Incyte Corporation is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| INCY | MQ | |
|---|---|---|
Market Cap | $23.11B | $1.85B |
Sector | Health | Technology |
52-Week High | $118.52 | $27.32 |
52-Week Low | $67.38 | $15.04 |
Enterprise Value | $19.13B | $1.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Marqeta (MQ) trades at $17.45, down slightly by 0.23% today. The stock shows a bullish technical signal with strong moving average support, though RSI levels indicate mixed momentum. Fundamentally, the company reported revenue of $624.88M in 2025 (source: company filing 2025) but a net loss of $13.93M, with profitability metrics like net margin at 0.33% remaining thin. A recent 1-for-4 reverse stock split was effective July 1, 2026 (source: Business Wire 2026-06-29), aimed at boosting the share price amid restructuring efforts.
The outlook is cautiously optimistic with analyst consensus price target at $19.00 (source: MarketBeat 2026), implying potential upside, but high valuation ratios (P/E 436.88) and ongoing profitability challenges pose risks. Investor sentiment is mixed, balancing growth initiatives in Europe against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
